Literature DB >> 3132927

Soluble interleukin-2 receptors in systemic lupus erythematosus.

R E Wolf1, W G Brelsford.   

Abstract

We studied levels of soluble interleukin-2 receptors (IL-2R), which are released by activated lymphocytes, in 139 serum samples from 12 patients with systemic lupus erythematosus (SLE). Concentrations of soluble IL-2R were significantly increased in SLE patients compared with controls (P less than 0.001), and they were significantly higher in patients during active SLE defined by low C3 levels (P less than 0.001), low C4 levels (P less than 0.001), or proteinuria (P less than 0.05) than during inactive SLE. Elevated levels of soluble IL-2R correlated with hypocomplementemia in longitudinal studies (P less than 0.001). Measurement of serum concentrations of soluble IL-2R may provide a sensitive and specific method for monitoring disease activity and immune activation in patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132927     DOI: 10.1002/art.1780310605

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  51 in total

Review 1.  The use of laboratory tests in the diagnosis of SLE.

Authors:  W Egner
Journal:  J Clin Pathol       Date:  2000-06       Impact factor: 3.411

Review 2.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

3.  Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis.

Authors:  P Airò; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Ann Rheum Dis       Date:  1991-04       Impact factor: 19.103

4.  Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus.

Authors:  Y Tokano; A Murashima; Y Takasaki; H Hashimoto; K Okumura; S Hirose
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

5.  Evaluation of serum levels of soluble interleukin-2 receptor as an indicator of disease activity in systemic lupus erythematosus.

Authors:  P Airŏ; S Braga; E Prati; D Brugnoni; M Bettinzioli; R Gorla; R Cattaneo
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

6.  Is soluble CD25 antigen (interleukin-2 receptor) a useful parameter for differential diagnosis of thyrotoxicosis?

Authors:  M Hüfner; M Wermann; M Grussendorf; B Heilig
Journal:  Clin Investig       Date:  1992-02

7.  Interleukin-2 receptor gene polymorphism in Chinese patients with systemic lupus erythematosus.

Authors:  Chang-Hai Tsai; Chung-Ming Huang; Sui-Foon Lo; Lei Wan; Fuu-Jen Tsai
Journal:  Rheumatol Int       Date:  2006-02-25       Impact factor: 2.631

8.  Soluble IL-2 receptor and CD25 cells in psoriasis: effects of cyclosporin A and PUVA therapy.

Authors:  J I Duncan; C Horrocks; A D Ormerod; A V Powles; P H Whiting; L Fry; A W Thomson
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

9.  Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state.

Authors:  Jakub Swadzba; Teresa Iwaniec; Jacek Musial
Journal:  Rheumatol Int       Date:  2009-12-15       Impact factor: 2.631

10.  Continuity of cytokine activation in patients with familial Mediterranean fever.

Authors:  Sait Bagci; Bulent Toy; Ahmet Tuzun; Yuksel Ates; Murat Aslan; Ali Inal; Mustafa Gulsen; Necmettin Karaeren; Kemal Dagalp
Journal:  Clin Rheumatol       Date:  2004-05-01       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.